{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:12:39Z","timestamp":1771632759451,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00228-024-03690-w","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T15:01:37Z","timestamp":1713538897000},"page":"1181-1187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients: a meta-analysis"],"prefix":"10.1007","volume":"80","author":[{"given":"Xiding","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiangyong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haishan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingfei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"1","key":"3690_CR1","first-page":"3","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C (2020) Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology 34(1):3\u201378","journal-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology"},{"issue":"1","key":"3690_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s002130000503","volume":"152","author":"M Dettling","year":"2000","unstructured":"Dettling M, Sachse C, Brockm\u00f6ller J, Schley J, M\u00fcller-Oerlinghausen B, Pickersgill I, Rolfs A, Schaub RT, Schmider J (2000) Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 152(1):80\u201386","journal-title":"Psychopharmacology"},{"key":"3690_CR3","first-page":"137","volume":"82","author":"JY Khokhar","year":"2018","unstructured":"Khokhar JY, Henricks AM, Sullivan EDK, Green AI (2018) unique effects of clozapine: a pharmacological perspective. Advances in pharmacology (San Diego, Calif) 82:137\u2013162","journal-title":"Advances in pharmacology (San Diego, Calif)"},{"issue":"1","key":"3690_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0b013e31827a813b","volume":"33","author":"FA Mustafa","year":"2013","unstructured":"Mustafa FA (2013) Schizophrenia past clozapine: what works? J Clin Psychopharmacol 33(1):63\u201368","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"3690_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/WNF.0b013e3181a620b2","volume":"32","author":"R Stryjer","year":"2009","unstructured":"Stryjer R, Timinsky I, Reznik I, Weizman A, Spivak B (2009) Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol 32(5):290\u2013292","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"3690_CR6","first-page":"285","volume":"54","author":"D van Dam","year":"2012","unstructured":"van Dam D, Bosch TM, Mookhoek EJ, Hovens JE (2012) Treatment of clozapine-induced tachycardia with propranolol complicated by psoriasis. Tijdschr Psychiatr 54(3):285\u2013289","journal-title":"Tijdschr Psychiatr"},{"issue":"1","key":"3690_CR7","first-page":"84","volume":"32","author":"D Brennan","year":"2024","unstructured":"Brennan D, Lal S, Hugo F, Waters F (2024) Clozapine-related tachycardia: a conundrum to identify and treat 32(1):84\u201388","journal-title":"Clozapine-related tachycardia: a conundrum to identify and treat"},{"issue":"4","key":"3690_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2125.1995.tb04472.x","volume":"39","author":"K Yoshimoto","year":"1995","unstructured":"Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T (1995) Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers\u2013N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39(4):421\u2013431","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3690_CR9","first-page":"909","volume":"22","author":"Y Masubuchi","year":"1994","unstructured":"Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S (1994) Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug metabolism and disposition: the biological fate of chemicals 22(6):909\u2013915","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"3","key":"3690_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bph.14884","volume":"177","author":"EC Tolledo","year":"2020","unstructured":"Tolledo EC, Miksys S (2020) Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses. Br J Pharmacol 177(3):701\u2013712","journal-title":"Br J Pharmacol"},{"issue":"4","key":"3690_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/138920007780655469","volume":"8","author":"M Chetty","year":"2007","unstructured":"Chetty M, Murray M (2007) CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 8(4):307\u2013313","journal-title":"Curr Drug Metab"},{"issue":"3","key":"3690_CR12","first-page":"1355","volume":"260","author":"V Fischer","year":"1992","unstructured":"Fischer V, Vogels B, Maurer G, Tynes RE (1992) The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260(3):1355\u20131360","journal-title":"J Pharmacol Exp Ther"},{"key":"3690_CR13","first-page":"370","volume":"28","author":"B Stolz","year":"2015","unstructured":"Stolz B, McCollum B (2015) Clozapine levels rise and fall with propranolol: A case report. J Pharm Pract 28:370","journal-title":"J Pharm Pract"},{"issue":"19","key":"3690_CR14","first-page":"1950","volume":"41","author":"X Yang","year":"2021","unstructured":"Yang X, Zhu R, Yan Q, Yang L, Li J, Fan X, Chen J, Wu H, Fang P (2021) Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients. Chinese Journal of Hospital Pharmacy 41(19):1950\u20131954","journal-title":"Chinese Journal of Hospital Pharmacy"},{"issue":"1","key":"3690_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1","journal-title":"Syst Rev"},{"issue":"8","key":"3690_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.5414\/CP203864","volume":"59","author":"X Yang","year":"2021","unstructured":"Yang X, Yan Q, Yang L, Li J, Fan X, Chen J, Wu H, Cai H, Zhu R, Fang P (2021) Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: a randomized, two-period, crossover study. Int J Clin Pharmacol Ther 59(8):578\u2013584","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3690_CR17","unstructured":"Food And Drug Administration (2017) Drug development and drug interactions: table of substrates, Inhibitors and Inducers"},{"key":"3690_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fnins.2018.00203","volume":"12","author":"JWY Yuen","year":"2018","unstructured":"Yuen JWY, Kim DD, Procyshyn RM, White RF, Honer WG, Barr AM (2018) Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neurosci 12:203","journal-title":"Front Neurosci"},{"issue":"2","key":"3690_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/BF00429215","volume":"73","author":"JM Kane","year":"1981","unstructured":"Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S (1981) Clozapine: plasma levels and prolactin response. Psychopharmacology 73(2):184\u2013187","journal-title":"Psychopharmacology"},{"issue":"3","key":"3690_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","volume":"24","author":"CR Young","year":"1998","unstructured":"Young CR, Bowers MB Jr, Mazure CM (1998) Management of the adverse effects of clozapine. Schizophr Bull 24(3):381\u2013390","journal-title":"Schizophr Bull"},{"issue":"1","key":"3690_CR21","first-page":"11","volume":"48","author":"FA Mustafa","year":"2015","unstructured":"Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M (2015) \u201cSchizophrenia past clozapine\u201d: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry 48(1):11\u201314","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"3690_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00131746-200509000-00003","volume":"11","author":"AY Khan","year":"2005","unstructured":"Khan AY, Preskorn SH (2005) Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 11(5):289\u2013301","journal-title":"J Psychiatr Pract"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03690-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:05:31Z","timestamp":1720163131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03690-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03690-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols and informed consent forms of all included bioequivalence studies were approved by the ethics committee of the Second Xiangya Hospital of Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}